drugset
drugset / Trial / NCT02309762

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers

NCT02309762 ↗

Phase 1 Completed 54 enrolled Fountain Biopharma Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of single-ascending IV doses of FB825

Timeline

Start
2015-03
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject FB825 Unknown 0.003 mg/kg Intravenous
Subject FB825 Unknown 10 mg/kg Intravenous

Indications

No indication recorded.